- Policy
- The budget for Paxlovid's SE relief will be prepared
- by Lee, Jeong-Hwan Nov 18, 2022 06:04am
- The Welfare Committee approved a budget of 1.7 billion won. Payment can be made next year if the plenary session is passed. The budget for relieving abnormal cases and side effects of drugs being administered in Korea through the EUA system, which is not approved based on the current Pharmaceutical Act, is smoothly being secured. This is beca
- Policy
- Quick diagnosis is essential for Hepatitis C
- by Nov 18, 2022 06:03am
- Pharmaceutical companies such as BMS, Gilead, and Abbvie introduced direct anti-virus (DAA) treatments, and hepatitis C opened the era of complete recovery. Re-treatment options for a small number of patients who failed to treat also appeared this year. The goal of hepatitis C is to find "hidden patients" who have not yet been diagnosed. Expe
- Policy
- Budget increase for drugs and vaccines under NA review
- by Lee, Jeong-Hwan Nov 17, 2022 05:54am
- The proposal to set a new budget worth KRW 14.4 billion to support the patients’ medical expenses of ultra-high-priced new drugs for rare diseases will be reviewed by the Adjustment Subcommittee of the National Assembly’s Special Committee on Budget and Accounts. A plan to increase the budget for the K-global vaccine fund project by KRW
- Policy
- Use of Evusheld extended to the severely immunocompromised
- by Kim, Jung-Ju Nov 16, 2022 06:10am
- The COVID-19 Vaccination Response Promotion Team (Head: KDCA Commissioner Kyung-Ran Baek) announced that it had expanded the eligibility of Evusheld as of the 14th to protect the severely immunocompromised from the next wave of COVID-19 outbreak that may arise in the winter season. With the expansion, blood cancer patients, transplant rec
- Policy
- Negotiations on Strepto, concluded in the early 20% range
- by Lee, Tak-Sun Nov 15, 2022 05:39am
- Major pharmaceutical companies of the anti-inflammatory enzyme Streptokinase and Streptodornase have reportedly reached an agreement with the NHIS in redemption negotiations. The recovery rate, which has been an issue, is said to be in the early 20% range. It is interpreted as the result of the two sides' concessions to each other. According
- Policy
- The vaccine fund will be increased by ₩40 billion
- by Lee, Jeong-Hwan Nov 14, 2022 06:07am
- Expectations in the pharmaceutical industry are soaring as the National Assembly's Health and Welfare Committee decided to increase next year's budget for the "K-Global Vaccine Fund" to 50 billion won, up 40 billion won from the government's plan. As the Ministry of Health and Welfare is constantly sending signals to the pharmaceutical com
- Policy
- Some companies give up negotiations to recover Strepto
- by Lee, Tak-Sun Nov 11, 2022 05:51am
- Some pharmaceutical companies with the anti-inflammatory enzyme Streptokinase-streptodornase have conveyed to the NHIS that they are not willing to negotiate. Currently, about five of the 37 pharmaceutical companies subject to negotiation are known to have given up negotiations. However, as the end of the negotiations approaches, more phar
- Policy
- Will expedited listing be possible within the year?
- by Lee, Tak-Sun Nov 10, 2022 05:46am
- The implementation of the measure that allows expedited listing for serious disease treatments is expected to be deferred somewhat. Although the government started the opinion collection process with the goal of implementing the measure in November, government officials see the measure to be implemented at the end of December at the ear
- Policy
- We will do our best to compensate for Paxlovid side effects
- by Lee, Jeong-Hwan Nov 10, 2022 05:45am
- Oh Yoo-kyung, head of the Ministry of Food and Drug Safety, said she would focus on budget and legislation to compensate for side effects and damage relief for drugs approved for emergency use for the treatment of COVID-19. Oh Yoo-kyung said she will immediately process the patient's compensation as soon as the results of the side effect revi
- Policy
- Drug prices should be raised if RWD show high effect
- by Lee, Tak-Sun Nov 9, 2022 05:47am
- Jin Yong Lee, Director of the Health Insurance Review and Assessment Research Institute, expressed his personal view that the government should raise the prices of high-priced drugs that confirm improved outcomes with real-world data (RWD). Currently, the Health Insurance Review and Assessment Service conducts performance analysis for s
